Concerning different anti-MMP-9 strategies, humanized anti-MMP-9 monoclonal antibodies (ANDECALIXIMAB) have been explored in gastric cancer patients, and found to be safe (with no indication of musculoskeletal side effects) and moderately effective when combined with classical cytotoxic drugs (Table 2) [141]. This evidence concerns the gene MMP9 and gastric cancer.